|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
SFRP5 methylation may be a novel DNA-based biomarker potentially useful in clinical breast cancer management.
|
18356147 |
2008 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
CTD_human |
In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
|
18283316 |
2008 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
|
18283316 |
2008 |
|
Malignant neoplasm of breast
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
We have previously reported that expression of the Wnt antagonist genes SFRP1 and SFRP5 is frequently silenced by promoter hypermethylation in breast cancer.
|
18990230 |
2008 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
SFRP5 methylation may be a novel DNA-based biomarker potentially useful in clinical breast cancer management.
|
18356147 |
2008 |
|
Breast Carcinoma
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
We have previously reported that expression of the Wnt antagonist genes SFRP1 and SFRP5 is frequently silenced by promoter hypermethylation in breast cancer.
|
18990230 |
2008 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
|
18283316 |
2008 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
|
18283316 |
2008 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
|
18283316 |
2008 |
|
Mammary Neoplasms
|
0.320 |
PosttranslationalModification
|
group |
LHGDN |
Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.
|
18356147 |
2008 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
In the present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
|
18283316 |
2008 |
|
Colorectal Carcinoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
The mRNA levels of SFRP1 and SFRP5 were significantly downregulated in 85 and 80% of CRC, respectively; but SFRP4 was overexpressed in 16 of 20 CRC samples.
|
19730886 |
2010 |
|
Colorectal Neoplasms
|
0.310 |
PosttranslationalModification
|
group |
LHGDN |
Silencing of secreted frizzled-related protein genes in MSI colorectal carcinogenesis.
|
18795670 |
2009 |
|
Colorectal Carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
[The role of secreted Wnt-antagonist genes hypermethylation in early detection of colorectal tumor].
|
17923031 |
2007 |
|
Colorectal Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
[The role of secreted Wnt-antagonist genes hypermethylation in early detection of colorectal tumor].
|
17923031 |
2007 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.
|
18283316 |
2008 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.
|
18283316 |
2008 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The results showed that curcumin combined with 5 μM DAC may inhibit cancer cell colony formation, migration through EMT (epithelial-mesenchymal transition) process regulation, total DNMT activity, especially in DNMT3a protein expression, and may also regulate tumor suppressor gene SFRP5 expression involved in the Wnt/β-catenin signaling pathway.
|
31754130 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
SFRP5-transfected xenograft tumors showed a reduction in the percentage of Ki-67-positive proliferating cells and an increase in terminal deoxynucleotidyl transferasebiotin-dUTP nick end labeling-positive cells.
|
30787036 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
For non-neoplastic mucosa a four marker panel (APC1A, SFRP4, SFRP5, SOX7) had modest accuracy (AUC = 0.68; 95% CI: 0.62,0.73) in predicting associated bowel neoplasia through the methylation signature of distant non-neoplastic colonic mucosa.
|
30473377 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Finally, in a xenograft animal model, we illustrated that the SFRP5 overexpression suppressed the tumor growth by decreasing angiogenesis and declined lung metastasis.
|
30584334 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Aberrant methylation of APC gene was statistically significant associated with age over 50 (p = 0.017), DDK3 with male (p < 0.0001), SFRP4, WIF1, and WNT5a with increasing tumor stage (p = 0.004, p = 0.029, and p = 0.004), SFRP4 and WIF1 with tumor differentiation (p = 0.009 and p = 0.031) and SFRP2 and SFRP5 with histological type (p = 0.001 and p = 0.025).
|
25107489 |
2014 |
|
Neoplasms
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
In conclusion, this is the first report documenting that the sFRP-5 is downregulated by promoter methylation and histone acetylation and functions as a tumor suppressor gene by inducing apoptosis in RCC cells.
|
20340127 |
2011 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Several genes have been newly associated with gastric carcinogenesis, both through oncogenic activation (MYC, SEMA5A, BCL2L12, RBP2 and BUBR1) and tumor suppressor gene inactivation mechanisms (KLF6, RELN, PTCH1A, CLDN11, and SFRP5).
|
21054651 |
2010 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
We identified promoter methylation as the predominant mechanism of SFRP5 gene silencing since SFRP5 promoter methylation correlated significantly with loss of SFRP5 expression in cell lines (P = 0.040) and primary tumors (P = 0.003).
|
18356147 |
2008 |